IntegraGen dans Business Times : transformer les progrès de la génomique en valeur concrète

IN THE NEWS

INTEGRAGEN PRESENTS RESULTS OF A STUDY EXTENDING THE IMPACT OF MIR-31 EXPRESSION MEASUREMENT TO STAGE III COLON CANCER PATIENTS AT ESMO 2018

October 21, 2018

Analysis of samples from the PETACC 8 phase III clinical trial shows that miR-31 expression levels identify sub-populations of cancer patients... Read More
INTEGRAGEN NOMINATED FOR THE GALIEN MEDSTARTUP AWARD 2018

September 19, 2018

IntegraGen has been nominated for the Prix Galien MedStartup 2018, a joint initiative between the Galien Foundation and Business France to encourage and reward international partnerships between... Read More
GOPATH LABORATORIES ANNOUNCE THE LAUNCH OF THE MIR-31NOW TEST

1 June 2018

GoPath Laboratories today announced the launch of a new proprietary test, miR31nowTM, at the annual convention of ASCO (the American Society of Clinical Oncology) being held... Read More

March 11, 2026

RESULTS OF MIR-31-3P EXPRESSION ANALYSIS IN THE FIRE-3 STUDY TO BE PRESENTED AT THE ASCO 2016 CONGRESS

May 19, 2016

he results of mir31-3p expression analysis in the FIRE-3 colon cancer study... Read More
INTEGRAGEN CONVENES SCIENTIFIC COMMITTEE TO REVIEW LATEST MIR-31-3P CLINICAL DATA

February 16, 2016

IntegraGen convened its Oncology Scientific Committee at the 2016 Gastro Intestinal Symposium in... Read More